Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based President operating in the Medical space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Arjun Purkayastha
Senior Vice President – eCommerce, Digital & Ventures of Reckitt
Arjun Purkayastha is a purpose driven leader with extensive global experience managing diverse businesses and multi-cultural teams at FTSE Top 10 and Fortune 100 companies – RB and P&G. He has a strong track record of building outperforming teams, iconic brands & innovative business models across 60+ countries having lived & worked in the UK, Singapore, South Korea and India. He currently leads eCommerce, CRM, digital, DNVB & start up ventures globally for RB with P&L, strategic and operational responsibility of all online channels & customers. He serves on the Board of Directors of 4 high growth, online focused companies – Pharmapacks.com (one of the largest and best 3P resellers on Amazon), Bombay Shaving Company (leading men’s wellness company in India), UpSpring (mom & baby products) and Healthily by Your.MD (AI powered self care). He is also an Investment Committee Member of Founders Factory & RB’s JV focused on Hygiene & Home start ups.
Follow Arjun Purkayastha:
About Reckitt: Reckitt Benckiser Group is a consumer goods company makes health, hygiene and home products.
Shaun Grady
Vice-President Business Development Operations of AstraZeneca
Shaun Grady has responsibility for Global Business Development at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including externalisation, licensing and partnering, M&A, and divestments. Shaun was appointed to his current role in 2013 with the creation of the Global Product and Portfolio Strategy (GPPS) unit. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010-13) and Vice President, Corporate Business Development (2006-10). Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca. Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT), led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ-BMS Diabetes Alliance. In addition, he has spent time in the US business managing the legal function and also completed a two year secondment to HR, leading a global People Strategy change project. Shaun is an Honorary Fellow in Entrepreneurship at Cambridge Judge Business School and is a member of the Board of Cambridge United Football Club and Cambridge Arts Theatre. Based in Cambridge, Shaun enjoys rugby and football, and occasionally turns his hand to sports writing.
Follow Shaun Grady:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Emmanuel Ligner
President & CEO, Life Sciences of GE Healthcare
Emmanuel joined GE Healthcare in April 2008, following its acquisition of Whatman International Plc. Since 2008, Emmanuel has held various positions in GE Healthcare Life Sciences. Working both in the UK and in the US, he managed the North America BioProcess business. In January 2012, Emmanuel took charge of the Commercial part of the then Life Sciences business, across EMEA, later expanding his role to include global commercial leadership of BioProcess. In January 2016, Emmanuel was name General Manager of the Core Imaging business which he held until he was named President and CEO of Life Sciences In July 2017. Emmanuel first entered the biopharma industry in Japan, joining Ostuka Pharmaceutical International Ltd as a Medical Representative in Tokyo. After five years in Ostuka in various roles, Emmanuel joined Abbott Japan, occupying positions such as Marketing Director Diagnostic Division and Commercial Director Diabetes Care Division. After 10 years in Japan, Emmanuel moved to the UK as Vice President Sales & Marketing Europe for Whatman International Plc.
Follow Emmanuel Ligner:
About Cytiva, GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Jan Makela
President and CEO, Imaging at GE Healthcare of GE Healthcare
Jan Makela is the President & CEO of GE Healthcare Global Services. Appointed in December 2017, he oversees the global development and execution of GE Healthcare’s service solutions and operations around the globe.
Follow Jan Makela:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Kieran Murphy
President & CEO of GE Healthcare
Kieran Murphy is President and CEO of GE Healthcare, a $20 billion business unit of General Electric that provides transformational medical technologies and solutions to the global healthcare industry. GE Healthcare supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life-sciences. Prior to this, Kieran was President and Chief Executive Officer of GE Healthcare Life Sciences, a $3.7 billion molecular medicine business that provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for diagnostics, therapy selection and treatment monitoring in patient care. Kieran was appointed CEO in May 2011 and oversaw significant revenue growth and geographic expansion of the molecular medicine business. Kieran joined GE Healthcare in 2008 from Whatman plc, a $230 million global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Kieran has over twenty years’ experience in the global life sciences and biotechnology industry, beginning his career with Janssen Pharmaceutical, a division of Johnson and Johnson, followed by leadership roles with Mallinckrodt, veterinary medicines provider Vericore, Novartis, Adprotech, ML Laboratories and Innovata plc.
Follow Kieran Murphy:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Dominic Casserley
President of Willis Towers Watson
Dominic Casserley became CEO of Willis Group in January 2013 following a nearly 30 year career at McKinsey & Company, the leading global management consulting firm. During his three decades at McKinsey, he was based in the United States, Asia and, most recently, in London where he served as Managing Partner, responsible for the firm’s offices in London and Dublin.
Follow Dominic Casserley:
About Willis Towers Watson: Willis Towers Watson is a global advisory and solutions company that helps clients around the world turn risk into a path for growth.
Jeanne Bolger
Vice President Venture Investing of Johnson & Johnson Development Corporation
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Follow Jeanne Bolger:
About Johnson & Johnson Development Corporation, Pulmocide: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Victoria Kitcatt
Vice President and Assistant General Counsel of Pfizer
Follow Victoria Kitcatt:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Dipankar Bhattacharjee
President & CEO: Generics Europe of Teva Pharmaceutical Industries
Mr. Dipankar Bhattacharjee was appointed President and CEO, Generics Europe in April 2013. Mr. Bhattacharjee joined Teva as Chief Executive Officer, Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including Vice President, Commercial in both Europe and Asia-Pacific regions, and Corporate Vice President and President, Asia Pacific Region. Mr. Bhattacharjee began his career at Nestlé SA and Bank of America. Mr. Bhattacharjee received a BA in Economics from St. Stephens College, University of Delhi, and a Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.
Follow Dipankar Bhattacharjee:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Michael Gibbs
Co-founder & President of Second Nature
Cambridge pharmacology graduate, strategy consultant, entrepreneur, author, health and nutrition geek. Incredibly strong believer in immersing yourself in the details of science and physiology – rather than the face value of published scientific papers – in order to come to a critical viewpoint on nutrition and public health. “It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgement of trusted physicians or authoritative medical guidelines” – Marcia Angell, long-time editor of the New England Journal of Medicine.
Follow Michael Gibbs:
About Second Nature: Second Nature is a digital programme that helps people lead healthier lives
Martin Lachs
Vice President Global Project Management of ICON plc
Follow Martin Lachs:
About ICON plc: ICON is a global provider of outsourced drug development services to biopharma, medical device, biosimilar and generic organizations.
Ian Wilson
Executive Vice President – Strategy & Development of Amcor
Ian Wilson is an Executive Vice President – Strategy and Development at Amcor.
Follow Ian Wilson:
About Amcor, Control Risks, The Cheltenham Ladies’ College: Amcor is a provider of packaging solutions in Australia, Western Europe, North America.
Eric Reynolds
Senior Vice President – Chief Marketing Officer of The Clorox Company
Follow Eric Reynolds:
About The Clorox Company: The Clorox Company (NYSE: CLX) is a leading multinational manufacturer and marketer of consumer and professional products.
Nina Kataria
Senior Vice President, Global Human Resources of Circassia
Nina Kataria joined Circassia in June 2014 to lead the company’s HR function. She brings to Circassia over 25 years’ experience of Human Resources, and has significant experience of the life sciences industry. Most recently, she was Human Resources Director at Lonza Biologics PLC, where she had strategic and operational responsibilities in the UK and internationally. Previously, she was the UK Human Resources Manager at Innovex (part of Quintiles), following roles of increasing responsibility at companies that are now part of Toyota and Unilever. She is a Fellow of the Chartered Institute of Personnel and Development (CIPD) and holds a post-graduate diploma from the Institute. She graduated from Thames Valley University in Business and Finance.
Follow Nina Kataria:
About Chartered Institute of Personnel and Development, Circassia: Circassia is dedicated to point of care asthma diagnosis and management.
Mustapha Rashid
President of British Orthopaedic Trainees Association
Follow Mustapha Rashid:
About British Orthopaedic Trainees Association: Supporting the orthopaedic trainees of today, for the patients of tomorrow
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Christopher Vann
Senior Vice President, Chief Operating Officer of Autolus
Christopher Vann leads commercial activities for Autolus. An industry veteran with 30 years’ experience in both development and business roles, he joined Autolus from Hoffmann-La Roche’s Swiss headquarters, where he was latterly responsible for leading the lung cancer commercial team and general management of the Tarceva brand. He has extensive experience of global lifecycle management of oncology products as well as implementing marketing strategy at a regional and national level. This includes launching several oncology, immunology and transplant products in countries such as China, Japan, Romania, Russia, South Africa, the UK and the USA. He gained his degree in toxicology and pharmacology from the School of Pharmacy, University of London.
Follow Christopher Vann:
About Autolus: Autolus is in T-cell programming and manufacturing technology.
Simon Viggers
Vice President Human Resources of Otsuka Pharmaceuticals
Simon Thule Viggers is a Senior HR Leader with deep global experience. Almost 20 years of experience within Pharma, 15 years in leadership roles across three continents. Proven ability to lead through challenging change and with an ability to approach business in a holistic way. Simon takes the starting point in the business agenda and translates that into actions for the organization and the people. Simon has a strong leadership background as he has been part of executive teams for more than a decade and has been preferred coach to many executives.
Follow Simon Viggers:
About Otsuka Pharmaceuticals: Otsuka Pharmaceuticals is a pharmaceutical company that operates throughout the globe.
Gareth Ridge
Senior Vice President of Operations & Site Head of Cambridge Epigenetix
Gareth has a degree in Pharmacology from the University of Cambridge and has worked in the pharmaceutical sector for over 20 years. During his career he has worked for both large and small pharma, biotechnology and clinical research organisations, he also has five years’ experience in business consultancy. In addition to delivering successful clinical research projects Gareth has managed business change projects – including system implementations, process reengineering and organisational change. He has held many leadership positions with responsibility for project and revenue delivery and strategic growth and has had oversight of over 70 clinical research studies, either directly as project manager or as responsible head, and has worked in high growth companies where he successfully built a team to successfully deliver 700% growth in project delivery & revenue in 2 years.
Follow Gareth Ridge:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Joanna Holbrook
Senior Vice President of Research of Cambridge Epigenetix
Joanna started her career in GSK R&D, working for seven years in the UK bioinformatics department, processing the integrating ‘omic data for drug target identification and validation mostly focussing on neurological disease, and then for three years in GSK USA Oncology R&D working on biomarkers for targeted therapies. She then left GSK and the USA for Singapore and built an academic group in A*STAR Singapore Institute for Clinical Sciences. Her group focused on epigenomic trackers of complex disease, especially the interaction of genetic, environmental and disease states in shaping the human epigenome. Her work in Singapore encompassed set-up of observational and interventional cohorts, biobanking, clinical databases, production, processing and analysis of biosample ‘omic profiles and multiple industrial collaborations. Moving back to the UK five years later, she took up a professorship at the University of Southampton, still working on epigenomics and also integration of electronic health record data to clinical cohorts. Most recently she has been VP of Translational Medicine at BenevolentAI, a fast growing British Biotech, where she initiated and led integration of ‘omic data into a large biomedical knowledge graph and machine learning approaches to analyses of patient-level data for precision medicine.
Follow Joanna Holbrook:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Patrick Darby
Executive Vice President, General Counsel & Corporate Secretary of Encompass Health Corp.
Patrick Darby was named executive vice president, general counsel and corporate secretary of HealthSouth in February 2016. Prior to joining us, Darby was a partner of the law firm of Bradley Arant Boult Cummings LLP, in Birmingham, Alabama. He is listed in Chambers USA, The Best Lawyers in America and Alabama Super Lawyers. He received his bachelor’s degree from Dartmouth College and his law degree from Washington & Lee University School of Law, where he was editor-in-chief of the Washington & Lee Law Review.
Follow Patrick Darby:
About Encompass Health Corp.: Encompass Health Corp. (HealthSouth), is an owner and operator of inpatient rehabilitation hospitals.
Lindsay Edwards
Chief Technology Officer and President of Platform of Relation Therapeutics
Lindsay Edwards is the Chief Technology Officer and President of Platform of Relation Therapeutics.
Follow Lindsay Edwards:
About GlaxoSmithKline, Relation Therapeutics: Relation Therapeutics engages in humanizing drug discovery and development.
William Richardson
Executive Vice President of Savaria Corp
Follow William Richardson:
About Savaria Corp: Savaria provides accessibility solutions for the elderly and physically challenged to increase their mobility and independence.
Benjamin T Dake
President & Founder of Aerovate Therapeutics
Ben Dake has 15 years experience as an Entrepreneur, Scientist and Biotech Investor. He founded Aerovate to develop therapies with the potential to meaningfully change the treatment of rare diseases. Informed by his training in diseases of aberrant proliferation he views PAH drug development through a unique lens focusing Aerovate on anti-proliferative therapies that directly address the root cause of disease.
Follow Benjamin T Dake:
About Aerovate Therapeutics: Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
Nick Child
Vice President of Stablepharma Ltd
Nick Child – Vice President & Co Founder Experienced company leader, business developer, multi-disciplined & experienced in UK & International markets, manufacturing & distribution. Initiated various start-ups, acquisitions, & funding rounds.
Follow Nick Child:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Paul Marcun
Executive Vice President, Chronic Care of Coloplast Denmark
Paul Marcun is the Executive Vice President of Chronic Care at Coloplast.
Follow Paul Marcun:
About Coloplast Denmark: Coloplast is a Danish company that develops and markets products and services related to ostomy, urology, continence, and wound care.
Clive Morris
President & Chief Executive Officer of Inivata
Follow Clive Morris:
About Inivata: Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
Bryan Olin
Senior Vice President of LivaNova
Bryan Olin, PhD is the Senior Vice President, Clinical, Quality & Regulatory Affairs at LivaNova. Dr. Olin joined Cyberonics in May 2009 as Vice President, Quality. In August 2009, he assumed additional responsibility for Clinical Affairs, and in April 2011, his responsibilities were expanded again to include Regulatory Affairs. With the 2015 merger between Cyberonics and Sorin, his responsibilities expanded to include corporate-wide responsibilities for the clinical, quality and regulatory affairs functions at LivaNova. Prior to May 2009, Dr. Olin was employed at Zeltiq Aesthetics, Inc., a privately held medical technology company in the San Francisco area, where he served as Sr. Director, Quality Assurance since October 2007. Prior to Zeltiq Aesthetics, Dr. Olin was employed at the LifeScan and Cordis companies of Johnson & Johnson from 1999 to 2007, holding several positions of increasing responsibility in quality assurance, statistics and clinical data management. Dr. Olin began his career with Procter & Gamble in 1993 after obtaining his Ph.D. in Statistics from Iowa State University. He currently serves on the board of directors for the Medical Devices Innovation Consortium (MDIC) and as an industry representative on the Advisory Committee for The National Patient-Centered Clinical Research Network (PCORnet).
Follow Bryan Olin:
About LivaNova: LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment.
Lynn Purkins
Vice President & Chief Development Officer of Ziarco
Lynn Purkins is the vice president of clinical operations for Reneo Pharmaceuticals. Lynn has nearly three decades of drug development experience in large and small biotechnology companies. Before joining Reneo, Lynn was a founder and chief development officer at Ziarco Pharma, which was acquired by Novartis in 2017. Prior to Ziarco, Lynn held numerous roles at Pfizer, including clinical pharmacology, clinical operations and team leader for projects from target selection to clinical proof of concept. Her experience spans multiple therapeutic areas including dermatology, pain, respiratory and gastroenterology. Lynn received a Ph.D. in nutrition and immunology from University of Leeds and a B.S. in dietetics from Leeds Beckett University.
Follow Lynn Purkins:
About Ziarco: Ziarco develops therapeutic agents for treating inflammatory and allergic diseases.
Jim Knight
President of xRapid
Follow Jim Knight:
About xRapid: xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Stephen Langlois
Vice President of Actuarial of Coverys
Steve Langlois has been with Coverys since 1989 and manages the actuarial function for the entire organization as the vice president of actuarial. Langlois first joined the organization as an underwriting assistant and has worked as an underwriter, a statistical analyst and actuarial analyst during his tenure with Coverys. Langlois received a Bachelor of Arts degree in mathematics from Boston College and an associate degree in underwriting designation from the Insurance Institute of America.
Follow Stephen Langlois:
About Coverys: Coverys is a provider of medical professional liability insurance for physicians, hospitals, dentists and advanced practice providers.
Stephen Langlois
Vice President of Actuarial of Coverys
Steve Langlois has been with Coverys since 1989 and manages the actuarial function for the entire organization as the vice president of actuarial. Langlois first joined the organization as an underwriting assistant and has worked as an underwriter, a statistical analyst and actuarial analyst during his tenure with Coverys. Langlois received a Bachelor of Arts degree in mathematics from Boston College and an associate degree in underwriting designation from the Insurance Institute of America.
Follow Stephen Langlois:
About Coverys: Coverys is a provider of medical professional liability insurance for physicians, hospitals, dentists and advanced practice providers.
Brad Bailey
Vice President of Sales of Ivy Sports Medicine
Brad Bailey, Vice President of Sales brings over 19 years of experience in the medical device industry with a focus in Sales management and Marketing. He has extensive experience in building teams to execute sucessful product launches and realize sustained sales growth. Mr. Bailey has worked in and run sales organizations focusing in Sports Medicine, he was Director of Sales of the Sports Tissue and Biologics Division at ConMed Corportation. He has also held leadership positions with the Musculoskeletal Transplant Foundation (MTF), DePuy Spine and Spar Medical. Mr. Bailey graduated from Birmingham Southern College in 1993 with a B.S. in Management.
Follow Brad Bailey:
About Ivy Sports Medicine: Ivy Sports Medicine is a young, dynamic company with extensive expertise in the development and production of meniscus implants.
Douglas Anderson
Founder & Vice President of Global Advocacy of Optos
Founder & Vice President of Global Advocacy, Optos plc, Douglas has a 35 year business career yielding huge experience in almost every aspect, and at every level, of healthcare technology development and commercialisation; initially as a highly creative hands-on designer, then as a design manager and technology innovator, transitioning through sales and marketing, and finally into business leadership as a serial entrepreneur.
Follow Douglas Anderson:
About Optos: Optos operates as a medical retinal imaging company.
Robin Marriott
Co-Founder and Executive Vice President of Pharmaceutical Development of PowderMed
PowderMed at Co-Founder.
Follow Robin Marriott:
About PowderMed: PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology.
Jerome Declerck
Vice President Research & Develop,ment of Optellum
Follow Jerome Declerck:
About Optellum: Optellum develops an imaging biomarker for smart lung cancer detection.
Edward K. Aldag
Chairman, President and CEO of Medical Properties Trust
Edward K. Aldag is the Chairman, President, and CEO at Medical Properties Trust.
Follow Edward K. Aldag:
About Medical Properties Trust, MPT Operating Partnership: Medical Properties Trust, Inc. bridges the gap between the growing demand for high-quality healthcare.
Chris Arnold
President of Horizon Distributors
Follow Chris Arnold:
About Horizon Distributors: Horizon Distributors engages in the distribution of landscape and irrigation supplies for green industry professionals.
